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Minor groove binders: Some recent research in 
drug development 
Abedawn I. Khalaf* 
 
ABSTRACT 
The role of the naturally occurring polyamides 
distamycin and netropsin as antibacterial agents is 
described. Also, the importance of the modifications 
to the lipophilic and hydrophobic moieties is 
discussed. It has also been shown that these DNA 
minor groove binding compounds can be used to 
treat other diseases such as sleeping sickness 
when the right modifications have been employed. 
Examples of the synthetic strategy of these poly-
pyrroles are also highlighted in this review. 
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INTRODUCTION 
Over the past twenty years or so researchers have 
prepared and tested a large number of minor 
groove binders. These ligands were found to bind 
in the minor groove of duplex DNA. The majority 
of these were synthesised based on naturally 
occurring distamycin and netropsin; these are 
called lexitropsins. Netropsin and Distamycin 
(also called Distamycin A or stallimycin) are 
antibiotics produced by (Streptomyces netropsis 
or S. distallicus fermentation) [1-7]. Distamycin 
mainly inhibits DNA synthesis. It acts against 
Gram-positive bacteria, fungi and viruses and is 
used for the treatment of skin and mucosal 
infection caused by the herpes simplex, herpes 
zoster or Vaccinia virus [8]. Distamycin, an
 
oligomeric peptide antibiotic with antitumor
activities, shows affinity for DNA specific 
sequences. The naturally occurring polyamide 
antibiotics netropsin and distamycin bind within 
the minor groove of DNA at regions with four or 
five AT base pairs, respectively. Not surprisingly, 
the cytotoxicity of these compounds precluded 
clinical use [8, 9]. Based on gene expression of 
small molecule targeted sequence and control of 
gene switches, distamycin can be used as anti-
malarial and anti-angiogenesis drugs. It is always 
the aim of the medicinal chemists to produce 
analogues to distamycin and netropsin which have 
high affinity for DNA and at the same time should 
have sequence selectivity so that these new 
compounds can be used as drugs which have 
therapeutic value. There are several fields which 
could make use of these DNA binding molecules, 
one of which is the treatment of MRSA, hospital 
acquired infections caused by Staphylococcus aureus 
and it is known that in America alone there are 
around half a million patients who contract a 
staphylococcal infection. 
 
Synthesis of distamycin and netropsin 
analogues 
1. Antibacterial and antifungal activity 
There are several ways distamycin can be 
modified. Some of these modifications are 
associated with changing the head group, while 
others deal with the tail group. Other modifications 
were also carried out on the heterocyclic rings, 
i.e. changing the pyrrole rings to a variety of 
heterocyclic rings such as thiazole, imidazole,
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54 Abedawn I. Khalaf 
and Table 1. Two compounds that were prepared
and studied extensively alongside distamycin 1 
and netropsin 2 are Thiazotropsin A 3 and 
Thiazotropsin B 4. 
These polyamides were synthesised using a 
variety of coupling methods such as HBTU, 
dicyclohexylcarbodiimide DCC, or acid chloride 
coupling reactions. The amidines were prepared 
from the methylation of thioamides and finally the 
displacement of methane thiol by an aminopyrrole
 
furan, oxazole and thiophene. On the other hand, 
some of the amide linkages were also modified;
these can be replaced with an olefinic double 
bond or diazo groups. 
In 2007, Anthony et al. [10] reported the synthesis 
of a large number of lexitropsins with a variety of 
modifications to the head groups, tail groups and 
the heterocyclic moieties. In this review some of 
these modifications and the synthetic strategy
for these syntheses have been reported: Scheme 1 
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Scheme 1. Synthesis of minor groove binders [5, 6, 7]. Ar and R represent head groups; TG: tail group; 
N-methylpyrrole have been shown throughout as the linked components. Reagents: i: coupling agent: 
HBTU, dicyclohexylcarbodiimide DCC, or thionyl chloride; ii: H2/Pd-C then immediate reaction with the 
coupling partner after filtration of the catalyst; iii: MeI; iv: NaH; v: NaOH(aq). 
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Table 1. Activities of polyamides [8-13] against representative bacterial species. 
No. Compound Staphylococcus aureus Staphylococcus faecalis 
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All data are minimium inhibitory concentrations, given as µg mL-1. Organisms used: Staphlococcus aureus NCTC 6571. 
Streptococcus faecalis NCTC 775. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 Abedawn I. Khalaf 
in the thermal denaturation measurements.  The 
authors developed a new set of compounds 
containing diaromatic monoguanidinium and 
mono-2-aminoimidazolinium derivatives and a series 
of diaromatic mono- and bis-isouroniums as well 
as a series of asymmetric diaromatic guanidinium/ 
2-aminoimidazolinium dications Table 2: 
compounds 14-21. All the compounds studied by 
the authors contained a furamidine scaffold which 
had been modified by changing both the terminal 
cationic arms and the bridging furan part of the 
molecule. It was proposed that the cationic groups 
could bind to DNA in two ways: first through 
direct hydrogen bonds through the NH groups and 
second through water-mediated interactions with 
the bases. In this work the authors exchanged the 
amidinium cations with guanidinium, 2-amino-
imidazolinium, and isouronium cations. In these 
cases they aimed to enhance hydrogen bond 
contacts in the minor groove by increasing the 
number of hydrogen bond donors (NH groups in 
the guanidinium and 2-aminoimidazolinium cations) 
or introducing an additional hydrogen bond 
acceptor (an O atom in the isouronium cation). 
Also, it was hoped that the optimum linker would 
allow for a better orientation of the positive charges 
within the groove and introduce the curvature or
 
oligomer. The other class of compounds contained
stilbenoid head groups.  These were prepared either 
from the reaction of arylmethylphosphonates with 
aromatic aldehydes in the presence of sodium 
hydride [Horner-Wadsworth-Emmons conditions] 
or in the case of the pyridyl derivatives which was 
bearing an active methyl group; a condensation
reaction was used in the presence of zinc chloride, 
as a catalyst, in acetic anhydride. The esters 
formed were hydrolysed to give the corresponding 
carboxylic acids, which were coupled to the 
amino pyrrole derivatives: Scheme 1. 
2. Sleeping sickness 
Nagle et al. [11a] prepared and studied a large 
number of symmetric diaromatic bis-guanidinium 
and bis-2-aminoimidazolinium derivatives which 
are structurally related to furamidine and have the 
potential to treat sleeping sickness. Sleeping sickness 
is a chronic disease caused by Trypanosoma 
parasites, which affect the human central nervous 
system. Jackson et al. [11b] have generated a 
high-quality draft genome sequence for the strain 
of Trypanosoma brucei that is responsible for 
almost all reported cases of human African 
trypanosomiasis. Nagles compounds showed 
good affinity for DNA as noticed by an increase 
of the melting temperature (ǻTm) values observed
 
Table 2. Results obtained from the thermal melting experiments showing the 
change in melting temperature in the presence of the monoamidine-like cations 
[14-21] to Salmon Sperm DNA (ǻTm(SS), oC); melting temperature in phosphate 
buffer (10 mM) is 69
o
C. 
             
H2N
X
Y H2N
X
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N
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NH2 N
H
N
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HN
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NH2
Y= Y= Y=
 
No. X (ǻTm(SS), oC) (ǻTm(SS), oC) (ǻTm(SS), oC) 
14 CH2 3 - 3 - 2 
15 CH2CH2 - 0 - 0 - 
16 O - 2 - 0 4 
17 S - 2 - 0 2 
18 NH - 2 - 2 - 
19 Piperazine - 2 - 1 - 
20 CO - 0 - - - 
21 NHCONH - 2 - 4 - 
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optimization of the distance between the cationic
moieties (guanidinium and 2-aminoimidazolinium) 
for DNA binding. 
In 2009 Vooturi et al. [14] focused their work on 
the role played by the three-dimensional structure 
of DNA on gene expression [15]. They concentrated 
on the development of minor groove DNA 
binding agents with the potential to bend DNA. 
The design hypothesis of these agents consisted of 
connecting the sequence recognition properties of 
N-methylpyrroles to sterically bulky, hydrophobic 
groups that could force open the minor groove 
of DNA, resulting in a bend. As part of this 
project, approximately a dozen compounds were 
prepared, and on the basis of previous reports of 
antimicrobial activity of DNA binding agents, 
they examined these compounds for antibacterial 
activity against both Gram-positive and Gram-
negative bacteria.  Most of the agents displayed 
no antibacterial activity up to a concentration of 
32 mg/L. However, one compound, 22, gave MIC
  
 
geometry best suited to fitting in the groove.  
However, Boykin et al. have shown that linear 
molecules are also capable of strongly binding to 
the minor-groove [12]. Therefore the curvature is 
not essential to fit into the minor groove. This  
is also supported by the work carried out by 
Nguyen et al. [13]. This showed that in the linear 
molecule CPG- 40215A, the N,N’-diaminoguanidine 
bridging group served as a see-saw hinge 
facilitating a variety of interactions with the bases 
through motions that position the terminal 
amidines cations in a range of binding modes [13]: 
Figures 1 and 2. Moreover, to investigate the 
optimal linking scaffold, we have exchanged the 
furan moiety of furamidine for a number of 
smaller functional groups (O, S, NH, CO, CH2, 
CH2CH2, or NHCONH). It was assumed  that such 
a substitution should afford a 2-fold advantage by 
facilitating the interaction with DNA through 
Hydrogen bonds (as donors or acceptors), and as 
the cations are larger than in the furamidine series, 
making this central group smaller should ensure 
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Figure 1. Structure of furamidine (left) and general structure of the related compounds 
previously reported by Rozas group [27] that have shown good affinity toward DNA. 
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58 Abedawn I. Khalaf 
imidazole was used. The last part was the linker. 
As well the benzophenone, the authors reduced 
this moiety to the corresponding alcohol. Also, 
they used an aliphatic linker of approximately the 
same length as the benzophenone linker: Table 4, 
compounds 33-38. 
3. Studies of DNA displacement in bacteria 
Several extensive studies showed that there was 
no correlation between the DNA binding affinity 
and antibacterial activity. This was explained on 
the basis of the differences in the transport of these 
compounds into the bacterium and this consequently 
will lead to a lack of activity [10, 14, 18, 22]. 
Vooturi et al. [14] examined the binding ability of 
their own compounds to DNA in vivo using a 
Hoescht dye competition assay. The result of  
the incubation of Hoescht dye with bacteria was  
the formation of fluorescent bacteria. Individual 
compounds were then added into a solution 
containing the fluorescent bacteria and the changes 
in the fluorescence due to Hoechst displacement 
were measured. 
4. Antibacterial against vancomycin resistant 
Enteroccoci and methicillin resistant 
Staphylococcus aureus 
Dyatkina et al. [24] reported the synthesis of a 
selected group of novel, pyrrole tetraamides, their
DNA binding properties, and antibacterial 
activities. Substantial potency against vancomycin 
resistant Enterococci (VRE) and methicillin 
resistant Staphylococcus aureus (MRSA) was
 
values in the 8-16 mg/L range against VRSA, 
MRSA, and GISA. No activity was observed
against Gram-negative bacteria. This result is 
similar to published examples of DNA binding 
antibiotic (DBA) [16-25]. Although 22 did display 
antibacterial activity, the MIC values were too 
high to be useful, thus they decided to prepare a 
series of analogues of the lead agent in an effort to 
identify more potent molecules and to elucidate 
some of the key structural features of this 
molecule that were necessary for activity. 
The authors [14] designed their compounds on the 
basis of the tail region, which is the portion of the 
molecule that contains cationic groups Figure 3.  
It is known that the positive charge of the tail 
should interact with the negative charge on the 
phosphate backbone of DNA. The authors were 
also interested in the hydrophobic character of this 
region, since the tail also interacts with the 
hydrophobic part of the sugar residue located in 
the minor groove of DNA. It has been reported 
before that enhancing the hydrophobicity of the 
cationic tail could increase the binding affinity of 
the molecule to DNA and help the transport of the 
drug [16-20, 25]. The authors chose the following 
tail groups for the synthesis of their compounds: 
methylpiperazine, dimethylaniline, morpholine, 
piperidine, and pyrolidine: Table 3, compounds: 
23-32. The second part of the molecule they
investigated was the heterocyclic region. It was 
clear from the literature that the heterocyclic 
moiety can modify the antibacterial activity of the 
molecule [17, 19, 22, 26]. N-methylimidazole was 
chosen based on the enhanced activity when
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Figure 3. Conceptual breakdown of potent compound 22. The arrow indicates the axis 
of symmetry for the molecule. 
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This study showed that these short poly pyrroles 
with head-to-head geometry bind strongly to 
the minor groove of AT tracts of DNA. The 
comparison of the molecular modelling of these 
compounds to distamycin revealed improved 
hydrophobic interactions as well as improved 
hydrogen bonding to the floor of the groove. It 
appears that good DNA binding properties are a 
requirement for good antibacterial activity. The 
obvious conclusion from their studies is that 
lipophilic, alkyl substituents on the nitrogen atom 
of the pyrrole produced strong antibacterial 
activity as shown by submicromolar MIC values
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
observed. The authors found that strong DNA 
binding properties are necessary for antibacterial 
activity and that lipophilicity was a strong 
modulator of activity. They also optimised their 
library of compounds to reduce cytotoxicity 
toward human T-cells. Two groups of linked 
tetraamides shown in Tables 5 and 6 [24] were 
synthesized. Compounds 39-41: Table 5, which 
have linked pyrroles alkylated with methyl, propyl, 
and isoamyl groups, respectively, represent the 
first group. The second group (Table 6), compounds 
42-53: Table 6, presents N-isoamylpyrrole units 
linked with different dicarboxylic acids. 
 
 
 
 
 
 
 
Table 3. DNA binding affinity and in vitro antimicrobial activity of 23-32. 
           
O
H
N
H
N
OO N
XX
N O
NHR
O
RHN
 
No. R X KaATa 
105M-1 
VRSA 
(mg/L) 
MRSA 
(mg/L) 
23 N
 
CH 1.0 16 8 
24 N
N
 
CH 0.108 >32 >32 
25 
N
 
CH 0.391 >32 >32 
26 N
 
CH 0.679 2 1 
27 N
 
CH 0.931 1 5 
28 N
O
 
CH ND 8 4 
29 
N
 
N ND >32 >32 
30 N
 
N ND 32 32 
31 N
 
N ND 8 4 
32 N
O
 
N ND >32 >32 
aAssociation constant for binding to AT hairpin (5-CGAAAAA-
CAAAAAGTTTTTCG-3) as determined by the ethidium bromide 
displacement assay. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table 4. DNA binding affinity and in vitro antimicrobial activity for 33-38. 
                
H
NHN
OO NN O
NHR
O
RHN X
 
No X R KaATa 
106M-1 
VRSA 
(mg/L) 
MRSA 
(mg/L) 
33 OH
 
N
 
0.175 >32 >32 
34 OH
 
N
 
0.0098 >32 >32 
35 
 
N
 
0.154 >32 >32 
36 
 
N
 
0.0238 >32 >32 
37 (CH2)11  N
 
0.021 >32 >32 
38 (CH2)11  N
 
0.0125 >32 >32 
aAssociation constant for binding to AT hairpin (5-CGAAAAA-
CAAAAAGTTTTTCG-3) as determined by the ethidium bromide 
displacement assay. 
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Table 5. In vitro antimicrobial activity, cell toxicity, and DNA binding of terephthalamides. 
                           OO
HNNH NN RR
O
HN
O
NH
NH
H2N
HN
NH2
 
    MIC (µM)b   
 
Compound 
 
R 
ǻTm 
(oC)a 
 
MRSAc 
 
BM4147d 
 
UCD-3d 
Toxicity 
(%NCC)e 
Distamycin -------- 26 >45.5 >45.5 >45.5 79 
39 methyl 30 22.7 22.2 >45.5 56 
40 propyl 29 11.1 5.6 5.6 61 
41 3-methyl-butyl 28 1.4 0.7 0.7 4 
aǻTm, changes in the DNA melting temperature (ǻTm) of an AT-rich dodecamer, 
(CGATTATTAAGC).(GCTTAATAATCG), upon binding of an equimolar amount of compound. 
bMIC, minimal inhibitory concentration. cMRSA, methicillin resistant Staphylococcus aureus. 
dBM4147 and UCD3, two strains of VRE. eToxicity is measured as a fraction of growth as 
compared to no compound control (percent). 
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Table 6. In vitro antimicrobial activity, cell toxicity, and DNA binding for  
N-(3-methyl-butyl)-1H-pyrrole dimers with different linkers. 
                  
OO
H
NNH
NN
O
HN
O
NH
NH
NH2
HN
NH2
X
 
No X ǻTm(oC)  MIC (µM)  Toxicity %NCC 
       
   MRSA BM 
4147 
UCD-3  
42 
 
28 1.4 0.7 0.7 6 
43 
 
26 0.7 1.4 1.4 23 
44 
 
11 11.4 >45.5 >45.5 88 
45 
 
10 >45.5 >45.5 >45.5 87 
46 
N  
25 1.4 0.7 1.4 3 
47 N
 
11 2.8 22.7 22.7 6 
48 
N
N
 
20 2.8 2.8 2.8 32 
49 NO2
 
25 1.4 1.4 1.4 42 
50 
 
20 2.8 2.8 5.7 15 
51 
 
24 >45.5 >45.5 >45.5 0 
52 Me
 
24 0.7 1.4 1.4 38 
53 Me
Me  
12 11.4 >45.5 >45.5 75 
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against both MRSA and VRE. From the above 
data, it appears that the lipophilicity of the 
compounds may be related to improved cellular 
uptake, which modulates antibacterial activity for 
those compounds that exhibit sufficient strong 
DNA binding. As uptake would also increase for 
cells other than the bacterial targets, significant 
toxicity would be expected. Strong toxicity 
against human T-cells was indeed observed for 
some compounds, but this toxicity did not 
correlate with antibacterial activity or DNA 
binding. Also, it was found that the degree of 
toxicity is very sensitive to the alkyl substituents 
on the pyrrole units. 
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